Browsing: obesity

The healthcare sector is one of the best-performing sectors in the S&P 500 over the past month, with a gain of around 6%. But while that rebound has been led by a handful of mega-cap Big Pharma companies, it has also been reflected in the performances of smaller firms

In this free webinar, see how to design obesity trials that generate clinically meaningful, patient-relevant and payer-relevant evidence. Attendees will learn how to select endpoints that demonstrate broader metabolic, cardiovascular and patient-centered value. The featured speakers will discuss designing patient-centric obesity trials that better reflect real-world obesity management including the generation of evidence and longitudinal…

The increasing prevalence of obesity across the past decades represents one of the most pressing issues in public health, especially given the well-established role of obesity in modifiable health risk. Historically, obesity is known to disproportionately impact those of non-white ethnicities and low socioeconomic positionality. However, over the past five years, the UK has seen…

A novel study has found that obesity is associated with a distinct molecular program driving the transition from early-stage, premalignant breast lesions to invasive breast cancer. Rather than simply showing increased activation of classical invasive pathways, tumors from patients with obesity exhibited a distinct stress-adaptive phenotype. The findings from the study published by Hladik et…

I initiate coverage of MBX Biosciences (MBX) with a speculative buy rating. My thesis is substantiated by two-pillars: firstly, canvuparatide is a clinically de-risked, and once-weekly

Funding has been awarded for a new innovative programme to improve access to obesity support

July 5, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today recent submissions of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for ASC36, a once-monthly to once-quarterly next-generation peptide amylin receptor agonist and ASC36_35 FDC, a once-monthly injection co-formulation of ASC36 plus peptide GLP-1R/GIPR agonist ASC35,…

Babies exposed to higher levels of neurotoxin more likely to have difficulty controlling impulses later, research shows